Emerging Markets Turmoil Hits Bayer’s Consumer Health Business
This article was originally published in PharmAsia News
Executive Summary
Bayer has reported slower emerging market sales growth in its consumer health business due to an exposure to the overall geopolitical and macroeconomic situations in Russia and China, also being experienced by its competitors, but the German company assured investors that there is “nothing wrong with” its underlying business performance and perspective on long-term growth potential.